摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-[5-oxo-8-(4-pyrimidin-2-yloxyphenyl)-7-thioxo-6,8-diazaspiro[3.4]octan-6-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile | 1332390-83-6

中文名称
——
中文别名
——
英文名称
5-[5-oxo-8-(4-pyrimidin-2-yloxyphenyl)-7-thioxo-6,8-diazaspiro[3.4]octan-6-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile
英文别名
5-(8-Oxo-5-(4-(pyrimidin-2-yloxy)phenyl)-6-thioxo-5,7-diazaspiro[3.4]octan-7-yl)-3-(trifluoromethyl)picolinonitrile;5-[8-oxo-5-(4-pyrimidin-2-yloxyphenyl)-6-sulfanylidene-5,7-diazaspiro[3.4]octan-7-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile
5-[5-oxo-8-(4-pyrimidin-2-yloxyphenyl)-7-thioxo-6,8-diazaspiro[3.4]octan-6-yl]-3-(trifluoromethyl)pyridine-2-carbonitrile化学式
CAS
1332390-83-6
化学式
C23H15F3N6O2S
mdl
——
分子量
496.472
InChiKey
KWSKIGKYFHJMPD-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.7
  • 重原子数:
    35
  • 可旋转键数:
    4
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.22
  • 拓扑面积:
    127
  • 氢给体数:
    0
  • 氢受体数:
    10

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] THIOHYDANTOIN ANDROGEN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CANCER<br/>[FR] ANTAGONISTES DU RÉCEPTEUR DES ANDROGÈNES THIOHYDANTOÏNE POUR LE TRAITEMENT DU CANCER
    申请人:JANSSEN PHARMACEUTICA NV
    公开号:WO2018037342A1
    公开(公告)日:2018-03-01
    Disclosed are compounds, compositions and methods for treating and/ or ameliorating diseases, syndromes, disorders, or conditions associated with AR mutant receptors linked to castration-resistant prostate cancer, in a subject, including a mammal and/or human, in need thereof, who has demonstrated resistance to a first or second generation AR antagonist, comprising, consisting of, and/or consisting essentially of, administering to a subject in need thereof, a therapeutically effective amount of a compound of Formula (I) Formula (I) wherein R1, G, R10, and R11 are defined herein.
    本发明涉及化合物、组合物和方法,用于治疗和/或改善与与去势抵抗性前列腺癌相关的AR突变受体相关的疾病、综合征、障碍或病况,包括哺乳动物和/或人类在内,需要对第一代或第二代AR拮抗剂表现出抵抗性的对象。该方法包括、由以下组成或基本组成:向需要治疗的对象投与治疗有效量的I式化合物,其中R1、G、R10和R11在此被定义。
  • ANDROGEN RECEPTOR MODULATORS AND USES THEREOF
    申请人:Smith Nicholas D.
    公开号:US20130116258A1
    公开(公告)日:2013-05-09
    Described herein are compounds that are androgen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such androgen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon androgen receptors.
    本文描述了一些雄激素受体调节剂化合物。还描述了包括上述化合物的药物组合物和药物,以及使用这些雄激素受体调节剂,单独或与其他化合物组合使用,治疗与雄激素受体相关或依赖的疾病或病症的方法。
  • Androgen receptor modulators and uses thereof
    申请人:Smith Nicholas D.
    公开号:US09108944B2
    公开(公告)日:2015-08-18
    Described herein are compounds that are androgen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such androgen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon androgen receptors.
    本文描述了一些雄激素受体调节剂化合物。还描述了包括上述化合物的药物组合物和药物、以及使用这些雄激素受体调节剂,单独或与其他化合物联合使用的方法,用于治疗与雄激素受体有关的疾病或病情。
  • THIOHYDANTOIN ANDROGEN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CANCER
    申请人:Jaressen Pharmaceutica NV
    公开号:US20180008587A1
    公开(公告)日:2018-01-11
    Disclosed are compounds, compositions and methods for treating and/or ameliorating diseases, syndromes, disorders, or conditions associated with AR mutant receptors linked to castration-resistant prostate cancer, in a subject, including a mammal and/or human, in need thereof, who has demonstrated resistance to a first or second generation AR antagonist, comprising, consisting of, and/or consisting essentially of, administering to a subject in need thereof, a therapeutically effective amount of a compound of Formula (I) wherein R 1 , G, R 10 , and R 11 are defined herein.
  • US9108944B2
    申请人:——
    公开号:US9108944B2
    公开(公告)日:2015-08-18
查看更多